{"id": "179619", "url": "https://fevir.net/resources/Group/179619", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"], "versionId": "5", "lastUpdated": "2025-03-15T21:15:32.464Z"}, "name": "SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer", "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p>[No data.]</p></div>", "status": "empty"}, "title": "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Brian S. Alper"}}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as", "valueMarkdown": "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-06. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619#json."}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "179619", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}], "membership": "conceptual", "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "SystematicReviewEligibilityCriteria", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "SystematicReviewEligibilityCriteria"}]}}], "description": "**Study selection criteria**\nTypes of Studies.\nRandomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.\n\nTypes of participants.\nPatients aged \u226518 years with cytological or histological diagnosis of mHNPC.", "resourceType": "Group", "characteristic": [{"code": {"text": "Study Design"}, "exclude": false, "description": "Randomized controlled clinical trials (RCTs)", "valueCodeableConcept": {"coding": [{"code": "SEVCO:01003", "system": "https://fevir.net/sevco", "display": "randomized assignment"}]}}, {"code": {"text": "Study Design"}, "exclude": false, "description": "parallel design", "valueCodeableConcept": {"coding": [{"code": "SEVCO:01011", "system": "https://fevir.net/sevco", "display": "Parallel cohort design"}]}}, {"code": {"text": "Comparison"}, "exclude": false, "description": "compared the association of ADT and chemotherapy (docetaxel), versus ADT alone", "valueReference": {"type": "EvidenceVariable", "display": "GroupAssignment: ADT plus docetaxel vs. ADT alone"}}, {"code": {"coding": [{"code": "397669002", "system": "http://snomed.info/sct", "display": "Age"}]}, "method": [{"text": "applied to participants in the studies"}], "exclude": false, "description": "Types of participants.\nPatients aged \u226518 years", "valueQuantity": {"code": "a", "unit": "years", "value": 18, "system": "http://unitsofmeasure.org", "comparator": ">="}}, {"code": {"coding": [{"code": "64572001", "system": "http://snomed.info/sct", "display": "Disease (disorder)"}]}, "method": [{"text": "applied to participants in the studies"}, {"text": "cytological or histological diagnosis"}], "exclude": false, "description": "Types of participants.\nPatients with cytological or histological diagnosis of mHNPC.", "valueCodeableConcept": {"text": "metastatic hormone-naive prostate cancer"}}], "combinationMethod": "all-of"}